Adjuvant modulation of T-cell reactivity to 30-kDa secretory protein of Mycobacterium tuberculosis H37Rv and its protective efficacy against experimental tuberculosis

J Med Microbiol. 1999 Aug;48(8):757-763. doi: 10.1099/00222615-48-8-757.

Abstract

The immunoprotective behaviour of the 30-kDa secretory glycoprotein of Mycobacterium tuberculosis H37Rv has been investigated in different adjuvant systems in two mouse strains, NMR1 and C57BL/6J. In comparison with Freund's incomplete adjuvant (FIA) and dimethyldioctadecyl ammonium bromide (DDA), the 30-kDa glycoprotein complexed with polylactide-co-glycolide microparticles (PLG-MPs) induced maximum immunoreactivity in the two mouse strains. As compared with controls, immunisation with 30-kDa-PLG-MPs resulted in significantly greater protection in animals challenged with 1 x LD50 of M. tuberculosis H37Rv on the basis of survival rates and number of cfu in the infected organs 30 days after challenge. The degree of protection provided by 30-kDa-PLG-MPs was similar to that obtained with 30-kDa-FIA and higher than BCG immunisation. These findings suggest that biodegradable PLG microparticles can be used as an efficient carrier system for the key immunoprotective 30-kDa secretory protein antigen of M. tuberculosis H37Rv.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Amino Acid Sequence
  • Animals
  • BCG Vaccine / pharmacology
  • Bacterial Proteins / immunology
  • Bacterial Proteins / isolation & purification
  • Bacterial Proteins / pharmacology*
  • Female
  • Immunization
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred Strains
  • Molecular Sequence Data
  • Mycobacterium tuberculosis / immunology*
  • Survival Analysis
  • T-Lymphocytes / drug effects*
  • T-Lymphocytes / immunology
  • Treatment Outcome
  • Tuberculosis / microbiology
  • Tuberculosis / prevention & control*

Substances

  • Adjuvants, Immunologic
  • BCG Vaccine
  • Bacterial Proteins